SEC Form 10-Q filed by Nuwellis Inc.
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
No.
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(I.R.S. Employer
Identification No.)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
|
Smaller reporting company
|
|
Emerging growth company
|
Page Number
|
||
PART I—FINANCIAL INFORMATION
|
||
Item 1
|
3 | |
3 | ||
4 | ||
5 |
||
6 | ||
7 |
||
Item 2
|
18 | |
Item 3
|
27 | |
Item 4
|
27 | |
PART II—OTHER INFORMATION
|
||
Item 1
|
27 | |
Item 1A
|
27 | |
Item 2
|
30 | |
Item 3
|
31 | |
Item 4
|
31 | |
Item 5
|
31 | |
Item 6
|
31 |
September 30,
2024
|
December 31,
2023
|
|||||||
ASSETS
|
(Unaudited) |
|||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Accounts receivable
|
|
|
||||||
Inventories, net
|
|
|
||||||
Other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
Property, plant and equipment, net
|
|
|
||||||
Operating lease right-of-use asset
|
|
|
||||||
Other assets
|
|
|
||||||
TOTAL ASSETS
|
$
|
|
$
|
|
||||
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
|
||||||||
Current liabilities
|
||||||||
Accounts payable and accrued liabilities
|
$
|
|
$
|
|
||||
Accrued compensation
|
|
|
||||||
Current portion of operating lease liability
|
|
|
||||||
Other current liabilities
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Common stock warrant liability
|
||||||||
Operating lease liability
|
|
|
||||||
Total liabilities
|
|
|
||||||
Commitments and contingencies
|
||||||||
Mezzanine Equity
Series J Convertible Preferred Stock as of September 30,
2024 and December 31,
2023, par value $
|
||||||||
Stockholders’ equity
|
||||||||
Series A junior participating preferred stock as of September 30,
2024 and December 31,
2023, par value $
|
|
|
||||||
Series F convertible preferred stock as of September 30, 2024 and December 31, 2023, par value
$
|
||||||||
Preferred stock as of September 30, 2024 and December 31, 2023, par value $
|
|
|
||||||
Common stock as of September 30, 2024 and December 31, 2023, par value $
|
|
|
||||||
Additional paid‑in capital
|
|
|
||||||
Accumulated other comprehensive income:
|
||||||||
Foreign currency translation adjustment
|
(
|
)
|
(
|
)
|
||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
Total stockholders’ equity
|
|
|
||||||
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
|
$
|
|
$
|
|
Three months ended
September 30
|
Nine months ended
September 30
|
|||||||||||||||
2024
|
2023
|
2024 | 2023 | |||||||||||||
Net sales
|
$
|
|
$
|
|
$ | $ | ||||||||||
Cost of goods sold
|
|
|
||||||||||||||
Gross profit
|
|
|
||||||||||||||
Operating expenses:
|
||||||||||||||||
Selling, general and administrative
|
|
|
||||||||||||||
Research and development
|
|
|
||||||||||||||
Total operating expenses
|
|
|
||||||||||||||
Loss from operations
|
(
|
)
|
(
|
)
|
( |
) | ( |
) | ||||||||
Other income (expense), net
|
|
(
|
)
|
( |
) | |||||||||||
Financing Expense
|
( |
) | ||||||||||||||
Change in fair value of warrant liability
|
( |
) | ||||||||||||||
Income (loss) before income taxes
|
|
(
|
)
|
( |
) | ( |
) | |||||||||
Income tax expense
|
|
(
|
)
|
( |
) | ( |
) | |||||||||
Net income (loss)
|
$
|
|
$
|
(
|
)
|
$ | ( |
) | $ | ( |
) | |||||
Deemed dividend attributable to Series J Convertible Preferred Stock
|
||||||||||||||||
Net income (loss) attributable to common shareholders
|
$ | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||||
Basic and diluted net income (loss) per share
|
$
|
|
$
|
(
|
)
|
$ | ( |
) | $ | ( |
) | |||||
Weighted average shares outstanding – basic and diluted
|
|
|
||||||||||||||
Other comprehensive loss:
|
||||||||||||||||
Foreign currency translation adjustments
|
$
|
(
|
)
|
$
|
|
$ | ( |
) | $ | ( |
) | |||||
Total comprehensive income (loss)
|
$
|
|
$
|
(
|
)
|
$ | ( |
) | $ | ( |
) |
Outstanding
Shares of
Common Stock
|
Common
Stock
|
Additional
Paid in
Capital
|
Accumulated
Other
Comprehensive
Income
|
Accumulated
Deficit
|
Stockholders’
Equity
|
|||||||||||||||||||
Balance December 31, 2022
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
||||||||||||
Net loss
|
—
|
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||
Unrealized foreign currency translation adjustment
|
— | ( |
) | ( |
) | |||||||||||||||||||
Unrealized gain on marketable securities
|
— | |||||||||||||||||||||||
Stock-based compensation
|
|
|
|
|
|
|
||||||||||||||||||
Issuance costs related to 2022 common stock offering
|
— | ( |
) | ( |
) | |||||||||||||||||||
Conversion of preferred stock into common stock
|
||||||||||||||||||||||||
Reclassification of warrants to equity
|
— | |||||||||||||||||||||||
Conversion of warrants into common stock
|
||||||||||||||||||||||||
Balance March 31, 2023
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
||||||||||||
Net loss
|
— |
( |
) | ( |
) | |||||||||||||||||||
Unrealized gain on marketable securities
|
— | ( |
) | ( |
) | |||||||||||||||||||
Stock-based compensation
|
||||||||||||||||||||||||
Issuance costs related to ATM offering
|
— | ( |
) | ( |
) | |||||||||||||||||||
Issuance of common stock from ATM offering
|
||||||||||||||||||||||||
Balance June 30, 2023
|
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
Net loss
|
— | ( |
) | ( |
) | |||||||||||||||||||
Stock-based compensation | ||||||||||||||||||||||||
Balance September 30, 2023
|
$ | $ | $ | ( |
) | $ | ( |
) | $ |
Outstanding
Shares of
Common Stock
|
Common
Stock
|
Additional
Paid in
Capital
|
Accumulated
Other
Comprehensive
Income
|
Accumulated
Deficit
|
Stockholders’
Equity
|
|||||||||||||||||||
Balance December 31, 2023
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||
Net loss
|
—
|
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||
Unrealized foreign currency translation adjustment
|
— | ( |
) | ( |
) | |||||||||||||||||||
Stock-based compensation, net
|
|
|
|
|
|
|
||||||||||||||||||
Issuance of common stock from conversion of series J convertible preferred stock
|
||||||||||||||||||||||||
Series J convertible preferred stock deemed dividend
|
— | |||||||||||||||||||||||
Balance March 31, 2024
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||
Net loss
|
— |
( |
) | ( |
) | |||||||||||||||||||
Unrealized foreign currency translation adjustment
|
— | ( |
) | ( |
) | |||||||||||||||||||
Stock-based compensation, net
|
||||||||||||||||||||||||
Issuance of common stock, net |
( |
) | ( |
) | ||||||||||||||||||||
Balance June 30, 2024
|
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | |||||||||||||
Net loss
|
— | |||||||||||||||||||||||
Unrealized foreign currency translation adjustment
|
— | ( |
) | ( |
) | |||||||||||||||||||
Stock-based compensation, net
|
||||||||||||||||||||||||
Issuance of common stock net
|
||||||||||||||||||||||||
Exercise of common stock warrants
|
||||||||||||||||||||||||
Issuance costs
|
— | ( |
) | ( |
) | |||||||||||||||||||
Deemed dividend
|
— | ( |
) | ( |
) | |||||||||||||||||||
Reclassification of April 2024 warrants to equity
|
— | |||||||||||||||||||||||
Balance September 30, 2024
|
$ | $ | $ | ( |
) | $ | ( |
) | $ |
Nine months ended
September 30
|
||||||||
2024
|
2023
|
|||||||
Operating Activities:
|
||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Adjustments to reconcile net loss to cash flows used in operating activities:
|
||||||||
Depreciation and amortization
|
|
|
||||||
Stock-based compensation expense
|
|
|
||||||
Change in fair value of warrant liability
|
( |
) | ||||||
Warrant financing costs
|
||||||||
Net realized gain on marketable securities
|
( |
) | ||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
|
(
|
)
|
|||||
Inventory, net
|
|
|
||||||
Other current assets
|
(
|
)
|
(
|
)
|
||||
Other assets and liabilities
|
(
|
)
|
(
|
)
|
||||
Accounts payable and accrued expenses
|
(
|
)
|
(
|
)
|
||||
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
||||
Investing Activities:
|
||||||||
Proceeds from sale of marketable securities
|
||||||||
Additions to intangible assets
|
( |
) | ||||||
Purchases of property and equipment
|
(
|
)
|
(
|
)
|
||||
Net cash provided by (used in) investing activities
|
(
|
)
|
|
|||||
Financing Activities:
|
||||||||
Issuance of common stock from offering
|
||||||||
Proceeds from the exercise of Series J Convertible Preferred Warrants
|
||||||||
Proceeds from the exercise of April 2024 Warrants
|
||||||||
Issuance of July and August 2024 Common Stock and Warrants
|
||||||||
Proceeds from ATM stock offerings, net
|
||||||||
Payments on finance lease liability
|
( |
) | ||||||
Net cash provided by financing activities |
|
|
||||||
Effect of exchange rate changes on cash
|
(
|
)
|
(
|
)
|
||||
Net decrease in cash and cash equivalents
|
(
|
)
|
(
|
)
|
||||
Cash and cash equivalents - beginning of period
|
|
|
||||||
Cash and cash equivalents - end of period
|
$
|
|
$
|
|
||||
Supplemental cash flow information |
||||||||
Non-cash impact of conversion of warrants to common stock
|
$ | $ | ||||||
Reclassification of April 2024 warrants to equity
|
$ | $ | ||||||
Issuance of Series J Preferred Stock for exercise of warrants
|
$ | $ | ||||||
Issuance of Common Stock for conversion of Series J Preferred Stock
|
$ | $ | ||||||
Deemed dividend on Series J Preferred Stock
|
$ | $ |
(in thousands)
|
September 30,
2024
|
December 31,
2023
|
||||||
Finished Goods
|
$
|
|
$
|
|
||||
Work in Process
|
|
|
||||||
Raw Materials
|
|
|
||||||
Inventory Reserves |
( |
) | ( |
) | ||||
Total
|
$
|
|
$
|
|
September 30
|
||||||||
2024
|
2023
|
|||||||
Stock options
|
|
|
||||||
Warrants to purchase common stock
|
|
|
||||||
Series F convertible preferred stock
|
|
|
||||||
Series J convertible preferred stock | ||||||||
Total
|
|
|
Three months ended
September 30
|
Nine
months ended
September 30
|
|||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
(in thousands, except per share amounts)
|
||||||||||||||||
Net income (loss)
|
$
|
|
$
|
(
|
)
|
$ | ( |
) | $ | ( |
) | |||||
Deemed dividend attributable to Series J Convertible Preferred Stock
|
||||||||||||||||
Net loss attributable to common shareholders |
$ |
$ |
( |
) | $ |
( |
) | $ |
( |
) | ||||||
Weighted average shares outstanding
|
|
|
||||||||||||||
Basic and diluted loss per share
|
$
|
|
$
|
(
|
)
|
$ | ( |
) | $ | ( |
) |
trading days immediately following the date we effect a reverse stock split in the future and (iii) if we effect a reverse stock split prior to obtaining the Warrant Stockholder Approval, the lowest volume weighted average price for the trading days immediately following the date we obtain the Warrant Stockholder Approval. The Company secured the Warrant Stockholder Approval on June 6, 2024. Subsequent to June 30 2024, the number of shares underlying the common warrants were adjusted to
Underwriter and Placement Agent Fees: In connection with the offerings described above, the Company paid the underwriter or placement agent, as applicable, an aggregate cash fee of either
to to be determined at the discretion of our Board of Directors. On June 26, 2024, the Company’s board of directors approved a reverse stock split of the Company’s issued and outstanding shares of common stock (the
Three months ended
September 30
|
Nine
months ended
September 30
|
|||||||||||||||
(in thousands)
|
2024
|
2023
|
2024
|
2023
|
||||||||||||
Selling, general and administrative expense
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Research and development expense
|
|
|
|
|
||||||||||||
Total stock-based compensation expense
|
$
|
|
$
|
|
$
|
|
$
|
|
Three months ended
|
Nine months ended
|
|||||||||||||||
September 30
|
September 30
|
|||||||||||||||
2024
|
2023
|
2024
|
2023
|
|||||||||||||
Expected volatility
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||
Expected Life of options (years)
|
|
|
|
|
||||||||||||
Expected dividend yield
|
|
%
|
|
%
|
|
%
|
|
%
|
||||||||
Risk-free interest rate
|
|
%
|
|
%
|
|
%
|
|
%
|
●
|
Level 1 - Financial instruments with unadjusted quoted prices listed on active market exchanges.
|
●
|
Level 2 - Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over-the-counter traded financial instruments. The prices for the financial instruments are determined using prices for
recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
|
●
|
Level 3 - Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using
significant unobservable inputs or valuation techniques.
|
(in thousands)
|
||||
Balance at December 31, 2022
|
$
|
|
||
Change in fair value
|
|
|||
Issuance of Common Stock for exercise of Series I warrants |
( |
) | ||
October 17, 2023, issuance of Series J warrants | ||||
Exercise of Series J warrants | ( |
) | ||
Change in fair value | ( |
) | ||
Balance at December 31, 2023
|
|
|||
Exercise of Series J warrants
|
( |
) | ||
April 30, 2024, issuance of common warrants | ||||
Exercise of April 2024 warrants |
( |
) | ||
Reclassification of April 2024 warrants to equity
|
( |
) | ||
Change in fair value |
( |
) | ||
Balance at September 30, 2024 | $ |
Three months ended
September 30, 2024
|
Three months ended
September 30, 2023
|
Increase (Decrease)
|
% Change
|
|||||||||||
$
|
2,367
|
$
|
2,412
|
$
|
(45
|
)
|
(1.9
|
)%
|
(in thousands)
|
Three months ended
September 30, 2024
|
Three months ended
September 30, 2023
|
Increase (Decrease)
|
% Change
|
||||||||||||
Cost of goods sold
|
$
|
711
|
$
|
1,031
|
$
|
(320
|
)
|
(31.0
|
)%
|
|||||||
Selling, general and administrative
|
$
|
2,702
|
$
|
3,428
|
$
|
(726
|
)
|
(21.2
|
)%
|
|||||||
Research and development
|
$
|
486
|
$
|
1,117
|
$
|
(631
|
)
|
(56.5
|
)% |
Nine months ended
September 30, 2024
|
Nine months ended
September 30, 2023
|
Increase (Decrease)
|
% Change
|
|||||||||||
$
|
6,418
|
$
|
6,313
|
$
|
105
|
1.7
|
%
|
(in thousands)
|
Nine months ended
September 30, 2024
|
Nine months ended
September 30, 2023
|
Increase (Decrease)
|
% Change
|
||||||||||||
Cost of goods sold
|
$
|
2,097
|
$
|
2,718
|
$
|
(621
|
)
|
(22.8
|
)%
|
|||||||
Selling, general and administrative
|
$
|
10,544
|
$
|
13,582
|
$
|
(3,038
|
)
|
(22.4
|
)%
|
|||||||
Research and development
|
$
|
2,378
|
$
|
4,050
|
$
|
(1,672
|
)
|
(41.3
|
)%
|
ITEM 1. |
LEGAL PROCEEDINGS
|
ITEM 1A. |
RISK FACTORS
|
ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
ITEM 3. |
DEFAULTS UPON SENIOR SECURITIES
|
ITEM 4. |
MINE SAFETY DISCLOSURES
|
ITEM 5. |
OTHER INFORMATION
|
ITEM 6. |
EXHIBITS
|
Incorporated By Reference
|
||||||||||||||
Exhibit
Number
|
Exhibit Description
|
Form
|
File
Number
|
Date of First Filing
|
Exhibit
Number
|
Filed
Herewith
|
Furnished
Herewith
|
|||||||
Fourth Amended and Restated Certificate of Incorporation
|
10
|
001-35312
|
February 1, 2012
|
3.1
|
||||||||||
|
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation
|
8-K
|
001-35312
|
January 13, 2017
|
3.1
|
|||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation
|
8-K
|
001-35312
|
May 23, 2017
|
3.1
|
||||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation
|
8-K
|
001-35312
|
October 12, 2017
|
3.1
|
||||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation
|
8-K/A
|
001-35312
|
October 16, 2020
|
3.1
|
||||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation
|
8-K
|
001-35312
|
January 2, 2019
|
3.1
|
||||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation
|
8-K
|
001-35312
|
April 27, 2021
|
3.1
|
||||||||||
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation
|
8-K
|
001-35312
|
December 9, 2022
|
3.1
|
||||||||||
Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation
|
8-K
|
001-35312
|
June 26, 2024
|
3.1
|
||||||||||
Form of Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock
|
S-1/A
|
333-221010
|
November 17, 2017
|
3.7
|
||||||||||
Certificate of Designation of Preferences, Rights and Limitations of Series J Convertible Preferred Stock
|
8-K
|
001-35312
|
October 17, 2023
|
3.1
|
||||||||||
Second Amended and Restated Bylaws
|
8-K
|
001-35312
|
April 27, 2021
|
3.2
|
Incorporated By Reference
|
||||||||||||||
Exhibit
Number
|
Exhibit Description
|
Form
|
File
Number
|
Date of First Filing
|
Exhibit
Number
|
Filed
Herewith
|
Furnished
Herewith
|
|||||||
Third Amended and Restated Bylaws
|
|
|
|
|
X |
|||||||||
3.14 |
Amendment to Third Amended and Restated Bylaws
|
X | ||||||||||||
Form of Common Warrant
|
8-K
|
001-35312
|
July 25, 2024
|
4.1
|
||||||||||
Form of Common Warrant
|
8-K
|
001-35312
|
August 26, 2024
|
4.1
|
||||||||||
Form of Placement Agent Warrant
|
8-K
|
001-35312
|
August 26, 2024
|
4.2
|
||||||||||
Form of Securities Purchase Agreement
|
8-K
|
001-35312
|
July 25, 2024
|
10.2
|
||||||||||
Placement Agency Agreement dated July 24, 2024 between Nuwellis, Inc. and Roth Capital Partners LLC
|
8-K
|
001-35312
|
July 25,2024
|
10.1
|
||||||||||
Termination Agreement to the Supply and Collaboration Agreement, dated August 21, 2024
|
8-K
|
001-35312
|
August 22, 2024
|
10.1
|
||||||||||
Placement Agency Agreement dated as of August 23, 2024, by and between Nuwellis, Inc., and Ladenburg Thalmann & Co. Inc.
|
8-K
|
001-35312
|
August 26, 2024
|
10.1
|
||||||||||
Form of Securities Purchase Agreement
|
8-K
|
001-35312
|
July 25, 2024
|
10.69
|
||||||||||
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||||||||||
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||||||||||
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||||||||||
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||||||||||
101.INS
|
Inline XBRL Instance Document
|
X
|
||||||||||||
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document
|
X
|
||||||||||||
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
X
|
Incorporated By Reference | ||||||||||||||
Exhibit
Number
|
Exhibit Description | Form |
File
Number |
Date of First Filing
|
Exhibit
Number |
Filed
Herewith
|
Furnished
Herewith
|
|||||||
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
X
|
||||||||||||
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
X
|
||||||||||||
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
X
|
||||||||||||
104
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
|
X
|
Nuwellis, Inc.
|
|||
Date: November 12, 2024
|
By:
|
/s/ Nestor Jaramillo, Jr.
|
|
Nestor Jaramillo, Jr.
|
|||
President and Chief Executive Officer
|
Date: November 12, 2024
|
By:
|
/s/ Robert Scott
|
|
Robert Scott
|
|||
Chief Financial Officer
|
35